Emergent Biosolutions (EBS) said Wednesday it entered into a new credit agreement for an asset-based revolving loan facility, effective Sept. 30, with Wells Fargo Bank as administrative agent.
The credit agreement provides for revolving loan commitments of up to $100 million with a maturity date of 2029, the company said.
As of Sept. 30, Emergent said it had a cash balance of $150 million and undrawn access to $100 million under the loan facility.
Price: 8.48, Change: +0.01, Percent Change: +0.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.